Valneva SE Sponsored ADR (VALN) shares ended the last trading session 17.4% higher at $7.32. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

French biotech firm Valneva said on Thursday its COVID-19 vaccine candidate was efficient as a booster for people who had received the same shot as an initial vaccination.

Valneva obtains exclusive worldwide license for LimmaTech’s S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva’s R&D pipeline LimmaTech to receive upfront ...

Valneva’s COVID-19 vaccine, VLA2001, is the only inactivated whole-virus COVID-19 vaccine approved in Europe 36 and was the first COVID-19 vaccine to receive a full marketing authorization from ...

Valneva will provide a live webcast of its first quarter 2025 results conference call beginning at 3 p.m. CEST/9 a.m. EDT today. This webcast will also be available on the Company’s website.

5 Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ® - Valneva 6 Vaccines on the table as chikungunya outbreak intensifies in India - BlueDot ...

French drugmaker Valneva said on Wednesday it will conduct a trial about the use of its COVID-19 vaccine candidate VLA2001 as a booster jab following a mRNA vaccination or natural infection.

Shares of Valneva VALN have dropped 61.5% in the trailing 12 months compared with the industry’s 39.6% decline. This substantial decline was attributable to the revision for the supply of doses ...

Valneva SE: Underfollowed French Biotech, 2 Interesting Vaccine Approvals Expected By 23-25 Feb. 26, 2023 3:03 AM ET Valneva SE (VALN) Stock PFE, XLV, IBB XBI VALN 8 Comments ...

Valneva has been responding to the French government’s call for vaccine supply of IXCHIQ ® in La Reunion 1 as the island is going through a major chikungunya outbreak with ~ 40,000 confirmed ...

Valneva plans to monitor the durability of the antibody response in a subset of participants for at least five years as part of a dedicated persistence trial. But, with top-line lot-to-lot ...

Valneva previously announced an agreement with the U.K. to provide 190 million doses, and upon approval, plans to send 60 million doses to the U.K. in the latter half of 2021.